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Abstract 
Anti-epileptic medications, and valproate principally, are commonly prescribed teratogens. There is 
significant concern that we are not doing enough to educate clinicians and potential parents about 
the risks of valproate in pregnancy. There is clear advice from the Medicines and Healthcare 
products Regulatory Agency (MHRA) and the International League Against Epilepsy (ILAE) about the 
risks of valproate exposure in utero. Reviews and guidelines that are focussed on foetal risk however 
fall short in being able to fully replicate the complexity of a real clinical decision. Valproate is 
certainly life-changing if your child is one of the 10% with a major malformation or 30-40% with a 
neurodevelopmental disorder, but valproate is also potentially life-saving in the context of ensuring 
the best possible seizure control for some mothers with epilepsy. There are significant knowledge 
gaps regarding the risks to mothers who elect to take another drug, or to mother and baby if she 
comes off medication entirely. We also should be doing more to reduce rates of sudden unexpected 
death in epilepsy (SUDEP) which is recognised as a key target when evaluating all maternal deaths.   
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Introduction 
There is a common clinical paradox when selecting the correct treatment for a young woman with 
genetic generalised epilepsy. On one hand, you can reassure her that about 4 in 5 people will become 
seizure free, but on the other hand you know that the drug most likely to bring this about has 
significant deleterious effects. Valproate is a drug that can be life transforming if it controls your 
epilepsy, but it is highly controversial because of the high rates of neurodevelopmental problems 
associated with children exposed to it in utero. This clinical conundrum is even more acute when all 
other drugs have failed to yield adequate seizure control and the only efficacious option that remains 
is valproate.  
Thalidomide has become a touchstone for both the scientific and lay community when describing the 
potential scale of a drug-side effect problem. Just alluding to the drug ‘thalidomide’ conjures up both 
the widespread harm caused to an estimated 10,000 children world-wide, but also the battle to 
recognise this risk and restrict its use. The drug had and has many important medical uses, but when 
taken in early pregnancy to combat hyperemesis, affected children were born with significant limb 
deficits. Although withdrawn in the UK in 1961 it took a long campaign and press-support before there 
was a compensation settlement. Therefore, when The Daily Telegraph headline on 30th July 2009 
stated that valproate was responsible for ‘Worst child poisoning case since thalidomide’ – the 
connotation was stark and emotional (figure 1). I will discuss the many reasons why the thalidomide 
comparison is understandable, but also why the circumstances are significantly different. This will be 
with the specific aim of promoting the unanimous advice about valproate in pregnancy from many 
august agencies, while also recognising that there are important evidence gaps.  
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Figure 1: British newspapers respond to parental concern regarding valproate prescription in 
pregnancy  
 
Valproate exposure in utero 
Valproate is a recognised teratogen and the major cause of foetal anticonvulsant syndrome. An 
estimated 10.7% of children exposed to valproate in utero are born with a major congenital 
malformation (that is; a structural abnormality that is recognisable at birth) in comparison to an 
estimated 2% of un-exposed infants.[1] This produces the first two problems: 1) doctors are often 
poor at explaining risk; 2) patients are inexperienced in balancing these risks.  This is exacerbated 
when the research evidence produces population risks ‘a certain percent of affected children..’ 
whereas what we need is individualised risk ‘your chance of having an affected baby is..’. Equally, our 
prior experiences as physician and parent will sway the way we deal with perceived risk. The second 
issue is this – the fact that the concern regarding major malformations and valproate is so well known 
it has blinded us to the new scandal, the new relationship. We, as adult physicians have had ‘change 
blindness’ – we have failed to see that the threat of valproate is no longer limited to malformations at 
birth – but more far-reaching and life-changing developmental issues.  
The easiest associations to recognise are when infrequent exposures (unusual drug x) causes a 
dramatic, instant and infrequently occurring outcome. A much more challenging situation is when a 
drug which has been available since the late 1960s, such as valproate, produces a delayed and variable 
effect, such as poorer cognition. Recognition is even harder when the effect is in the patients’ 
offspring. This in part explains why the epilepsy community was so slow to recognise the extent of the 
risks.  
 
The evidence 
The mainstay of evidence is epidemiological and as a result we can draw correlations but cannot speak 
directly to causation. These sources are either large retrospective cohort studiesor they are smaller 
prospective studies. The pregnancy registries have been a great asset. Since 1996 The UK and Ireland 
Epilepsy and Pregnancy Register (www.epilepsyandpregnancy.co.uk) has been collecting information 
on women with epilepsy who became pregnant, with a view to determining the effect of anti-epileptic 
drug exposure on the developing foetus.  They currently have information on over 10,000 pregnancies 
and continue to collect around 800 new cases each year; about 25% of all eligible pregnancies. 
Typically, a mother with epilepsy will contact the register and complete a questionnaire about their 
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health, their epilepsy and their medication – before the outcome of the pregnancy is known. Although 
there are undoubtedly biases about which types of women are motivated to participate and the ability 
of researchers to fully identify malformations or developmental issues without examining each child, 
the scale and rigour of the registries mean that they yield comparable results to each other.  
The current concern is about adverse neurodevelopmental outcomes; intellectual impairment and 
autism. Prospective evidence that intellectual impairment could be identified in children as young as 
three came in 2009 as the NEAD study group published their landmark paper.[2]  At this stage the 
threats of anti-epileptic drugs were feared but not known – the relevant consensus guidelines by the 
American Academy of Neurology,[3] the American College of Obstetricians and Gynecologists,[4] and 
the International League against Epilepsy[5] did not differentiate between the anti-epileptic drugs. 
The authors identified 309 children exposed to anti-epileptic drugs in utero, 258 were tested at 2 or 3 
years using standardised age-appropriate tests. 53 were exposed to valproate, 73 to carbamazepine, 
84 to lamotrigine and 48 to phenytoin. The mean IQ of the children exposed to valproate was 92 (CI 
88-97) which is significantly lower than the IQs of the other groups of children (98(CI 95-102), 101(CI 
98-104) and 99(CI 94-104) respectively). This relationship was even more stark when the authors 
looked at smaller groups – high dose v low dose; the 22 children exposed to high dose valproate had 
a mean IQ of 87. Higher maternal IQs were related to higher child IQs (as expected) – except in the 
case of valproate. As expected, some children exposed to valproate had congenital malformations, 
and lower IQ – but these children alone did not explain the IQ differences. As expected this 
relationship was confirmed when the study group were retested at 6 years.[6] They helpfully 
demonstrated that breastfeeding did not increase the risks and conferred the expected benefits to 
infants’ IQ.[7]  
A Cochrane review of 22 observational prospective cohort studies and six register studies confirmed 
the observation of poorer neurodevelopmental outcomes of pregnancies exposed to valproate.[8] The 
effect is dose related and exacerbated by polytherapy. In 2015 the EURAP study group (an 
International registry of anti-epileptic drugs and pregnancy) published on 1224 pregnancies where 
valproate was taken alone and a further 364 where it was taken alongside another epilepsy drug. The 
rate of congenital malformation was 10% in children exposed to valproate (11.3% if exposed to 
valproate and lamotrigine, 11.7% exposed to valproate and another antiepileptic drug that wasn’t 
lamotrigine). However, the dose really mattered; when more than 1.5g of valproate was used these 
rates increased to 24% for valproate alone; 31% for valproate and lamotrigine; and 19.2% valproate 
and another drug.[9]  
In 2013 a Danish population based study of 655,615 children born 1996-2006 identified that mothers 
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who took valproate in utero were five times more likely to have a child diagnosed with autism. This 
equates to a rate of 4.4/100 risk of autism spectrum disorder and a 2.5/100 risk of autism in 
childhood.[10] Well-designed prospective studies have delineated the autistic traits in children.[11]  
 
Advice  
In January 2015 the Medicines and Healthcare Products Regulatory Agency (UK) took the important 
step of issuing a statement regarding the safety of valproate when taken in pregnancy.[12,13] This 
advice followed on from the European Medicines Agency in 2014 who recommended strengthening 
the restrictions on the use of valproate in women and girls. Physicians were quicker to release 
statements than governmental agencies; in 2009 the American Academy of Neurology recommended 
that valproate should be avoided in pregnancy whenever possible.[14]  
The MHRA stated “No-one should stop taking valproate without discussing it first with their doctor 
and the benefits of valproate treatment must be carefully balanced against the risks.”  This message 
was echoed by the French Health Minister, Marisol Touraine, earlier this year, who announced 
practical measures such as adding an illustration to the verbal warning on the medication-packaging, 
and altering doctors' prescription software to include targeted information.  The joint task force of the 
International League Against Epilepsy commission on European affairs and the European Academy of 
Neurology responded with a detailed letter.[15] Their advice included that women of child-bearing 
potential must use effective contraception during treatment.  
The apparently contrary advice is that women should remain on medication throughout pregnancy. 
This oft repeated edict is based, primarily, on the risk of convulsions on the health of the foetus. 
Although this intuitively feels like the safest advice, it has never been studied with sufficient rigor and 
our evidence primarily comes from extrapolation from studies of eclampsia (where the 
pathophysiology of the seizures is very different) and from experiments on rats. Papers attempting to 
identify the risks of seizures on gestational outcome are all limited by the fact that there is often 
something inherently different about women with epilepsy who either seize frequently or need 
multiple drugs to control their epilepsy.  A Thai study of 1016 women with epilepsy identified that 
49.5% had seizures in pregnancy. Women with epilepsy who had seizures during pregnancy were more 
likely to have lower educational achievement, to be unmarried, have a lower family income and their 
male partners were younger.[16] A study of 106 women with epilepsy on medication showed that 
babies of women who had one or more seizure in pregnancy were more likely to have a shorter 
gestational age, and a five-times higher risk of being born before term.[17] However the same study 
demonstrated that there were drug risks too – women taking two or more anti-epilepsy drugs were 
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more likely to have small for gestational age babies.  
 
There is a compulsory medical Birth registry in Norway and a study of 1900 women with epilepsy (66% 
on no medication) identified that the majority of the poorer outcomes were seen in women who had 
epilepsy significant enough to need drug control. Both groups (medication v. no medication) exhibited 
seizures in the neonatal period. There were perinatal deaths in both groups (0.6% v 0.7%) which was 
non-significant.[18] The advice that women should remain on their medication therefore does not 
equate that all women with epilepsy should be on medication in pregnancy. A UK study demonstrated 
that when pregnant, women with epilepsy were twice as likely to come off their medication – but 
should this have happened prior to conception?[19] We are currently unable to tell which women 
would be safe to trial a withdrawal of medication when offering pre-conception counselling.  
 
Genetic generalised epilepsy 
The majority of mothers with epilepsy who take valproate have GGE (genetic generalised epilepsy); 
the evidence for the genetic component is compelling and there is an increased risk of epilepsy in first-
degree relatives. The genetic architecture is complex and not yet fully elucidated.[20,21] Clearly the 
maternal ‘epilepsy genes’ plus any paternal contribution to risk can and will be transmitted to the 
infant. It is unknown whether parental genomic factors contribute towards valproate associated neuro 
developmental disorders. Are women with GGE, therefore, at greater risk of neurodevelopmental 
disorders in their children than women with a focal epilepsy? This is very hard to unpick 
becausecurrent practice is that valproate is the primary drug for GGE GGE is the only syndrome in 
which valproate could be justified in pregnancy, due to our understating of the risks. Many pregnancy 
registers and epidemiological studies have been unable to report maternal epilepsy syndrome 
accurately. A study of 248 valproate exposed pregnancies in 2008 identified that 126 had idiopathic 
generalised epilepsy and of these, 15 had a major malformation. They did not report on 
neurodevelopmental outcomes. Reports from other disorders are scanty – not least because women 
with migraine and bipolar tend to come off medication before pregnancy.[19] 
 
Scale of the problem 
One of the reasons why this is a bigger issue than thalidomideis that valproate in Europe and across 
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the world is much more frequently prescribed. Women with epilepsy have 1% of all pregnancies and 
valproate has been widely prescribed since the late 1960s.[22] It is estimated, therefore, that there 
are thousands of people in the UK living with iatrogenic valproate associated neurodevelopmental 
disorders. Valproate remains a commonly prescribed drug and in 2002 was the most commonly 
prescribed antiepileptic drug worldwide.[23] We know that there has been a decade long reduction 
in valproate prescription in women aged 14-45 years in Wales.[24] Valproate in 2000/2001 was the 
most prescribed drug to these women (45%) falling to 24% by 2009/10. Younger women (18 years and 
under) also saw valproate prescriptions fall from 74% to 46% during this period. Causing more concern 
however, current UK data (figure 2) demonstrates that there has been no overall shift in the number 
of units of valproate that are being prescribed in primary care from 2012 to date. There is a 
significantly sized persistent group that remain on the drug despite strong evidence and clear advice, 
why might this be?  
 
Figure 2. Total Number of items of sodium valproate prescribed by GP practices across England from 
January 2012 to January 2017. www.OpenPrescribing.net  EBM DataLab, University of Oxford, 
2017[43]  
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Figure 3. The graph shows the proportion of valproate items prescribed compared to all items 
prescribed for control of epilepsy. All CCGs are shown on the graph online. (www.OpenPrescribing.net, 
EBM DataLab, University of Oxford, 2017)[43] 
Figure 3 shows the variety in the prescription of valproate across CCGs in England compared to all 
drugs for the control of epilepsy. CCGs such as West Norfolk (far left) in December 2016 used 560 
items of valproate vs 9827 items for epilepsy in comparison to NHS Stockport (far right) which used 
2151 items of valproate compared to 14155 items for epilepsy control. This equates to a 2.6 fold 
difference across the UK (57 items of epilepsy per 1000 items to control epilepsy vs 152). Does the 
presence of a strong epilepsy community as indicated by a local neurosciences centre influence 
valproate prescription? (Figure 4). Epilepsy prevalence is highly correlated with levels of 
deprivation[25] – however the map in figure 4 is not a ‘deprivation map’ of England. CCGs in the top 
20% should embrace the challenge of reducing their valproate prescribing and learn how this is 
possible from the best performing CCGs. 
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Figure 4. A map showing the data from figure 3 – the geographical variability of valproate prescribing 
compared to all items for epilepsy. (www.OpenPrescribing.net, EBM DataLab, University of Oxford, 
2017)[43] There appears to be an East v West divide.  Some CCG areas of higher valproate prescription 
– do not have a neurosciences centre: NHS Cumbria, Herefordshire, South Tyneside, North Kirklees. 
There is a ‘M40-M25’ corridor of high prescription around Oxford and North and West London.  
 
Valproate is an effective drug 
One of the reasons the main reason that valproate is not like thalidomide is that we cannot simply 
stop prescribing it completely. Influential, UK-based, pragmatic clinical trials such as SANAD reinforce 
the clinical view that valproate is superior to many of the subsequent anti-epileptic drugs and is the 
most efficacious in genetic generalised epilepsy.[26] 716 patients were randomised to open-label 
lamotrigine, topiramate or valproate. Valproate was superior in terms time to treatment failure (a 
compound metric of ‘do people remain on the drug?’ combining both side effects and seizure control). 
Valproate’s strength was primarily in seizure control.  
Seizure control is not the only thing important to potential mothers with epilepsy – but it is important. 
Most quality of life outcomes correlate with seizure control; sleep, mood, anxiety, confidence, pain; 
all are worse when seizures are frequent. UK driving restrictions apply to almost all people with 
recurrent seizures, meaning that a mother with an absence seizure following a period of control must 
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surrender her licence for at least a year before a return to driving. This clearly has a negative 
consequence on employment and employability despite legislation to protect against overt 
discrimination.  
Furthermore, seizures themselves are not benign. The MBRRACE-UK (Mothers and Babies: Reducing 
Risk through audits and confidential enquiries across the UK) report in December 2014 recognised 
that “Epilepsy remains a high risk condition in pregnancy” continuing “multi-agency evidence-based 
guidelines are urgently required to standardise and improve the care of pregnant and postpartum 
women with epilepsy.” Epilepsy was a co-morbidity in 17 (7.8%) maternal deaths in pregnancy. Of the 
women who died in pregnancy not one was reported as taking valproate. Lamotrigine was the most 
commonly prescribed drug; the pharmacodynamics of lamotrigine mean that some clinicians regularly 
test levels in pregnancy, whereas many do not.[27] Fourteen deaths are reported on in detail, all are 
caused by poor seizure control; twelve were SUDEP (sudden unexpected death in epilepsy )  and two 
were drownings. .[28] Only two of these twelve who died from SUDEP had adequate seizure control 
prior to pregnancy and poor seizure control correlates with an increase in SUDEP risk. Furthermore a 
review of similar deaths over thirty years concluded that, between 1979-2008, although maternal 
deaths have decreased, the proportion related to epilepsy have increased.[29] Put bluntly, restricting 
efficacious drugs from women increases their risk of dying from their epilepsy. Even when a woman 
is not pregnant, epilepsy confers a twenty-fold increase in death because of SUDEP. SUDEP kills more 
Britons per year that asthma, or AIDS, or house fires. Hence when the International League Against 
Epilepsy issued their report in 2015, there were authors rebutting their advice with letters such as 
“Valproate still has a place in women with epilepsy”.[30] 
 
Valproate the drug 
Valproate was not the output of any rational drug discovery programme, rather a serendipitous 
accident. Pierre Eymard was performing experiments on rat-models of epilepsy in France in the early 
1960s. Valproic acid was used as a lipophilic vehicle for compounds that were water-insoluble. Each 
compound dissolved in the valproic acid was a very acceptable anti-epileptic agent, but so too was the 
control vehicle with no ‘active’ compound in it. Very quickly they moved to use sodium valproate in 
rabbits and then other groups performed the first in man studies in 1964. By 1967 it was marketed in 
France as Depakine – within five years of its discovery.[31]  
Valproic acid has several formulations and many indications including migraine prophylaxis, mood-
stabilisation and to a lesser degree pain control. This means that advicesuch as the MHRA advice needs 
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to be advertised widely beyond the narrow scope of neurology in secondary care. Valproic acid is 
theorised to have many modes of action: inhibition of GABA transaminase; suppression of repetitive 
neuronal firing through inhibition of voltage-sensitive sodium channels; it also has a histone 
deacetylase inhibitor function. The combination of a ‘happy accident’ discovery and a varied mode of 
action has stymied researchers as they have sought to identify what is it specifically about the 
molecule which confers the risk in pregnancy as they aim to design safer valproates.  
There are a number of possible and potentially overlapping explanations for the association between 
exposure to valproate in utero and neurodevelopmental disorders in children. These include: 1) There 
is a direct effect on brain development; 2) The association is genetic but pleiotropic, driven by genetic 
overlap between the maternal epilepsy and causes of neurodevelopmental disorder; 3) There is a 
‘gene x environment’ interaction and that a high genetic risk of genetic generalised epilepsy from the 
mother renders the developing child more susceptible to valproate’s effects on brain development; 
4) Valproate is potentially mutagenic, and that there is an excess of de novo mutation in the children 
exposed to valproate.  
What is telling is that one of the methods of modelling ‘autism’ in rats is to expose them to high doses 
of valproate in utero.[32] Rat models provide a better method of studying the direct brain effects of 
valproate.[33] Initially exposed rat pups show alteration in medial prefrontal cortex synaptic 
connectivity. Their principal neurons show decreased excitability but increased local connectivity, due 
in part to an up-regulation of NMDA receptor expression. The synaptic abnormalities in exposed rats 
persist into adulthood.  
 
Valproate is primarily used in the epilepsy syndrome genetic generalised epilepsy (synonymous with 
idiopathic generalised epilepsy.[26] This is a developmental epilepsy syndrome which often starts in 
childhood or teenage years and can be exacerbated by sleep-deprivation and alcohol. There are also 
neurocognitive problems associated which include some executive function difficulties and impulsivity 
problems.[34,35] This is partly why the cognitive outcomes in the offspring in this group were not 
recognised; in part maternal under-reporting and in part a paternalistic doctorly view that these 
borderline IQs may be commensurate with maternal abilities. However, in fairness, it is worth adding 
that experts were asking questions about the safety of epilepsy drugs in pregnancy as early as 1964 – 
prior to the introduction of valproate.[36] What we have not proven with sufficiently powered studies 
is the role that maternal epilepsy syndrome plays on the likelihood of neurodevelopmental outcomes 
in the child.[37] The reasons why this is crucial are laid out below.  
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Epilepsy is different 
In 2011, Phil Smith and I wrote that ‘Epilepsy is different’;[38] this Editorial was a call to re-examine 
the series of contradictions that surround epilepsy – such as: it is potentially invisible, yet stigmatising; 
controllable, yet a cause of sudden death; common, but so little is known about it by lay audiences. 
Another contradiction is that family studies and twin registries tell us that it should be highly heritable 
and yet we know surprisingly little about the genetic architecture of common epilepsies.[20] That 
transmissible genetic factors are important is incontrovertible and a recent paper identifies for the 
first time that these mutations are also those that are seen to cause severe childhood epilepsies with 
autism and intellectual disability.[39] 
There are several important research questions that need to be answered 
1. Why are some children preferentially affected and can this be determined by studying 
mothers – ideally prior to conception? Could we identify ‘high-risk’ and ‘low-risk’ women to 
personalise pre-conception counselling? 
2. Is valproate the only drug that is working in this way? Are there other drugs working via similar 
mechanisms that have a similar result but to a lesser degree and so are yet to be discovered? 
3. With the understanding now about very rare gene changes in people with common epilepsies; 
what role does the maternal epilepsy syndrome have on the child? Do women with migraine 
and bipolar have similar problems?  
4. Does valproate cause new mutations in the child? We know that these de novo mutations are 
an important cause of intellectual disability and autism. Approximately 40% of children with 
intellectual disability have a causative de novo mutation identifiable with genome 
sequencing.[39,40] The mechanisms by which any teratogen affects organogenesis are still 
unclear but there is a large overlap between mutagenicity and teratogenicity. As the evidence 
that valproate is a teratogen is indisputable, we have to consider whether it is mutagenic.[41] 
Valproate readily crosses the placenta and circulates in the embryo in higher concentrations 
than in maternal blood.  
 
Conclusions 
It is clear from consensus statements and an independent review of the evidence that valproate 
confers a risk of neurodevelopmental disorder to 10% of exposed infants. This risk and this rate is 
unacceptable to most mothers and when adequate pre-conception counselling is provided they will 
choose to withdraw from valproate and / or swap valproate for another drug. For women who have 
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frequent seizures the smallest dose of valproate that controls their seizures is best and polytherapy 
should be avoided (particularly combinations of valproate and topiramate).[42] The mother should be 
central in our decision making process and we should support her if, when appraised of all the 
evidence, she makes a decision to remain on valproate in pregnancy. She should not be made to feel 
selfish for considering maternal quality of life factors when making a decision. Tools for decision 
making such as the optiongrids.org are helpful when weighing up difficult choices such as these. 
We need to know how valproate causes neurodevelopmental disorders as the drug remains an 
important treatment for women with epilepsy. What is the risk to women with epilepsy and their 
children when they are unmedicated in pregnancy? When does the risk balance tip so that future 
advice becomes – remain on your drug, or if it is valproate – swap it if you can? In addition to the 
evidence gaps discussed above, I want to ask: has the time come for it to be compulsory to enrol all 
women who take valproate in to a national registry? Should we be formally consenting all women 
aged 14-45 who choose to take valproate, and should there be a national standard for this? 
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